1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About

Evox Therapeutics Limited

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2016

Location

Oxford UK

Primary Industry

Biotechnology

About

Based in Oxford, UK, founded in 2016 by Matthew Wood, Per Lundin, and Samir EL Andaloussi. Evox Therapeutics Limited operates as a biotechnology company that harnesses and engineer the natural trafficking capabilities intended to develop a novel class of biotherapeutics. In February 2021, the company received GBP 69.2 million in series C funding from Redmile Group, OrbiMed, Invus, Oxford Sciences Innovation, GV, and Cowen Healthcare Investments. The company develops exosome-based therapeutics that enable protein, antibodies, small molecules, and nucleic acid-based therapeutics to reach previously inaccessible tissues and compartments to treat rare diseases. The company's revenue generated from developing nucleic acid-based therapeutics treat for novel diseases. Evox Therapeutics Limited will support an exosome-based therapeutics pipeline, including the progression of several rare diseases, and plans to continue the development of its DeliverEX exosome drug platform.
Current Investors
Healthcare Royalty Partners, Borealis Ventures, GV

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.evoxtherapeutics.com
Company Stage
Series C
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.